Freenome to go public via a SPAC with Perceptive Capital Solutions Corp in a $240m deal.

Freenome, an early cancer detection company, to go public via a SPAC with a consortium of investors-backed Perceptive Capital Solutions Corp, a SPAC, in a $240m deal. "Our technology has been clinically validated through our pivotal PREEMPT CRC study and recent JAMA manuscript. We have secured the commercialization partnerships needed to support the expected launch of multiple tests in 2026. Perceptive Advisors and our other PIPE investors bring deep healthcare expertise and conviction in our approach to make multi-cancer detection personalized, accessible and part of routine care," Aaron Elliott, Freenome CEO.